secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0000950170-24-023838
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics prices $550M public offering of 6.47M shares at $85/share
-----------------------------------------------------------------------------

- Gross proceeds ~$550M from 6.47M shares at $85; underwriters have 30-day option for 970,650 additional shares.
- Net proceeds to fund development of VK2809, VK2735, VK0214 programs and general corporate purposes.
- Offering expected to close March 4, 2024; Morgan Stanley & Leerink Partners lead underwriters.
- Directors and executive officers subject to 90-day lock-up until May 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024023838/0000950170-24-023838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024023838/vktx-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer